Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 787-793

  Welch, Stephen A ^a   Hirte, Hal W ^b   Elit, Laurie ^b   Schilder, Russel J ^c   Wang, Lisa ^a   MacAlpine, Katrina ^a   Wright, John J ^d   Oza, Amit M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenic; CA125; Gemcitabine; Ovarian cancer; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; GEMCITABINE; SORAFENIB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON PERFORATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL OVARIAN CANCER; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77956799700     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e273a8     Document Type: Article

References (36)

1. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol. 1997;8:963Y968.
2. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811Y2818.
3. Yoneda J, Kuniyasu H, Crispens MA, et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst. 1998;90:447Y454.
4. Nishida N, Yano H, Komai K, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101:1364Y1374.
5. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099Y7109.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125Y134.
7. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505Y2512.
8. Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25:LBA1 (meeting abstracts).
9. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12:144Y151.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205Y216.
11. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679Y691.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1Y10.
13. Lund B, Hansen OP, Neijt JP, et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs. 1995;6:61Y62.
14. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89Y93.
15. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1343Y1345.
16. von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853Y855.
17. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266Y269.
18. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593Y596.
19. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811Y2818.
20. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699Y4707.
21. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331Y1337.
22. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol. 2003;21:3013Y3015.
23. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000;18: 1733Y1739.
24. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2008;26 (abstr 5537).
25. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol. 2008;26 (abstr 5521).
26. Biagi JJ, Oza AM, Grimshaw R, et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185. J Clin Oncol. 2008;26 (abstr 5522).
27. Matulonis UA, Berlin ST, Krasner CN, et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008;26 (abstr 5501).
28. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol. 2007;25 (abstr 5508).
29. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2007;25: 5165Y5171.
30. Cannistra SA, Matulonis U, Penson R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180Y5186.
31. Garcia AA, Hirte H, Fleming G, et al. Phase II trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago and Princess Margaret Hospital Consortia. J Clin Oncol. 2008;26:76Y82.
32. Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110:49Y55.
33. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2007;25: 5165Y5171.
34. Cannistra SA, Matulonis U, Penson R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180Y5186.
35. Garcia AA, Hirte H, Fleming G, et al. Phase II trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago and Princess Margaret Hospital Consortia. J Clin Oncol. 2008;26:76Y82.
36. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2008;26(abstract 5537).